Peptide Research: Ipamorelin – Studies, Research Use, and Scientific Background

What is Ipamorelin?

Ipamorelin is a selective synthetic pentapeptide growth hormone secretagogue (GHS) and ghrelin receptor agonist. In laboratory research, Ipamorelin is studied for its ability to stimulate endogenous growth hormone (GH) secretion, regulate appetite, and support metabolic and endocrine research in preclinical models.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Selective Growth Hormone Release: Research published in European Journal of Endocrinology (1998) demonstrated that Ipamorelin selectively stimulates growth hormone release in animal models with minimal effect on ACTH or cortisol.
  Jorgensen et al., 1998
• Metabolic and Endocrine Research: Laboratory studies have explored Ipamorelin’s utility in research on appetite, body composition, and the regulation of energy balance via ghrelin receptor pathways.
  Kraemer et al., 1998

Laboratory Research Applications

• Investigation of growth hormone secretion and regulation
• Preclinical models of metabolic and endocrine disorders
• Research on appetite regulation and energy balance
• Studies of ghrelin receptor agonist mechanisms

Mechanism of Action (in Research Context)

Ipamorelin selectively binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a), stimulating the release of endogenous growth hormone from the pituitary gland. Unlike some other GHS peptides, it produces minimal effects on prolactin, ACTH, or cortisol in laboratory settings.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of Ipamorelin:

• Common Dose Range (animal studies): 100–500 mcg/kg, administered subcutaneously or intravenously
• Duration: Typically 7–21 days, depending on experimental protocol